Evaluating PET/CT Imaging for Advanced Colorectal Cancer
The Role of 18F-FDG and 68Ga-FAPI PET/CT in the Diagnosis and the Efficacy Evaluation of Advanced Colorectal Cancer (peritoneal Metastasis With/without Other Metastases)
Ruijin Hospital · NCT06601075
This study is testing if two types of PET/CT imaging can help doctors see how well conversion therapy is working for patients with advanced colorectal cancer and peritoneal metastasis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ruijin Hospital (other) |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06601075 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of 18F-FDG and 68Ga-FAPI PET/CT imaging in assessing the outcomes of conversion therapy for patients with advanced colorectal cancer, particularly those with peritoneal metastasis. Participants will undergo imaging at baseline and again after three months of therapy, with results compared to histopathological and clinical assessments. The goal is to determine the prognostic value of these imaging techniques in this patient population.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with histologically confirmed colorectal cancer and suspected peritoneal metastasis.
Not a fit: Patients with a history of other malignant diseases in the last five years or severe mental health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve diagnostic accuracy and treatment evaluation for patients with advanced colorectal cancer.
How similar studies have performed: Other studies have shown promising results using PET/CT imaging in cancer diagnosis, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Histologically confirmed colorectal cancer, clinical or other imaging suspicion of peritoneal metastasis with or without other distant metastases. 2. Patients voluntarily enrolled in this study by signing an informed consent form 3. Age ≥ 18 years 4. Expected life expectancy ≥ 3 months 5. Adequate organ and bone marrow function 6. Willingness to adhere to the study protocol and follow-up programme Exclusion Criteria: 1. Pregnant or breastfeeding women. 2. Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix 3. Severe mental disease, uncontrolled epilepsy, or central nervous system disease 4. Subjects with current concurrent interstitial pneumonitis or interstitial lung disease, or subjects with previous interstitial pneumonitis or interstitial lung disease requiring hormonal therapy, or subjects with other conditions that may interfere with the judgement and management of immune-related pulmonary toxicity, e.g., pulmonary fibrosis, organising pneumonia (e.g., occlusive bronchiectasis), pulmonary fibrosis, organising pneumonia (e.g., occlusive bronchiectasis), pneumoconiosis, Drug-associated pneumonia, idiopathic pneumonia, active pneumonia, or severe pulmonary impairment on CT; and active tuberculosis
Where this trial is running
Shanghai, Shanghai Municipality
- Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine — Shanghai, Shanghai Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Jiajia Hu
- Email: jiajiahu@shsmu.edu.cn
- Phone: 13524945287
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Advanced Colorectal Cancer, 68Ga-FAPI PET/CT, diagnosis, advanced colorectal cancer, efficacy evaluation